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dialogue between health care authorities and the pharmaceutical industry to create 
true risk-sharing agreements.
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Risk-sHaRing scHemes in Poland - analysis and classification of Rss 
PRoPosed in ReimbuRsement aPPlication Received by aHtaPol in 2013
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Objectives: To analyze and classify the Risk-Sharing Schemes (RSSs) proposed in 
reimbursement applications received by Agency for Health Technology Assessment 
in Poland (AHTAPol) in 2013. MethOds: Risk-Sharing Schemes proposed in reim-
bursement applications received by AHTAPol in 2013 were quantitatively and 
qualitatively analyzed. The classification of the RSSs was conducted based on both 
Carlson’s approach and the Polish Act on the reimbursement of medicinal prod-
ucts. Results: In the studied period, 80 reimbursement applications for medicines, 
special purpose dietary supplements or medical devices were received by AHTAPol. 
Among them, there were 52 RSSs for 51, medical technologies. They were classified 
into 5 categories according to the Act on the reimbursement. The most common 
category was making the official sales price dependent on a pay-back of a part 
of the reimbursement obtained to the entity which is obliged to finance benefits 
with public funds (48.08%). Further categories were: making the official sales price 
dependent on the applicant providing supplies at a reduced price as specified in the 
negotiations on the price of the medicine (15.38%), making the official sales price 
dependent on the level of turnover of the medicine (11.54%) and making the level 
of the applicant’s revenues dependent on the health effects achieved (1.92%). Other, 
nonclassified RSSs constituted 23.08% of all. Among 52 proposed RSSs only 17 of 
them could be classified according to the Carlson’s approach. As a results, 10 Price 
Volume Agreements, 6 Manufacturer funded treatment initiation and 1 Conditional 
treatment continuation were identified. cOnclusiOns: Most of the propositions 
are not considered to be RSS according to the Carlson’s approach. The most common 
propositions were related to pay-back of a part of the reimbursement obtained for 
each reimbursed package and did not included any risk sharing. There is a strong 
need for further research.
HealtH caRe use & Policy studies – conceptual Papers
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WHateveR HaPPened to nice value-based PRicing? Welcome, value-
based assessment
Langham S.1, Gemmell E.2, Kerrigan M.1, Wright A.J.1, Chetty M.1
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For several years, there has been much discussion about the central role the National 
Institute for Health and Care Excellence (NICE) would play in the move to value-
based pricing (VBP) of drugs in England and Wales as part of the new Pharmaceutical 
Price Regulation Scheme (PPRS) scheduled to start in 2014. To date, there is no VBP 
model, but NICE and the PPRS have been disentangled, and NICE is currently con-
sulting on a proposal to include new terms of reference for value based assessment 
(VBA) in its Technology Appraisal Methods Guide. This would change the way in 
which it makes recommendations to the NHS and could become policy within a 
short time frame. Therefore, manufacturers need to be aware the implication of the 
VBA proposal on data requirements for NICE submissions. Currently, NICE reim-
bursement decisions are based on an incremental cost-effectiveness ratio threshold 
of £20,000/QALY, with factors such as innovation and National Health Service objec-
tives acting to increase the acceptable threshold up to £30,000/QALY, and end-of-life 
benefits potentially increasing the acceptable threshold further to £50,000/QALY. 
A key feature of the proposed VBA is the use of modifiers to numerically adjust 
the ICER (up to a maximum of 2.5 times the base ICER of £20,000/QALY, i.e £50,000/
QALY). The burden of the illness for which the drug is approved as well as its societal 
impact are two such modifiers. Precise guidance on applying burden of illness and 
societal impact modifiers to ICERs is currently lacking, although information may 
become available during summer 2014. However, there is some draft information 
on quantifying these modifiers. We will review all available information, including 
any post-consultation guidance, to provide an overview of data requirements and 
possible changes to cost-effectiveness models that manufacturers may need to 
consider for future VBAs.
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Objectives: A National immunization Technical Advisory Groups (NITAG) is a body 
of national experts that empowers and provides guidance to national health policy 
makers to enable them to make evidence-based decisions on immunisation. The 
aim of this study was 1) To develop a framework for the assessment of NITAGs that 
will allow to understand how closely their operations are aligned with best practice; 
2) to investigate whether differences with best practice are influenced by economic 
or geographic differences between countries; and 3) to understand the impact of 
NITAG alignment on the adoption of vaccines in the country’s national immunisation 
programme. MethOds: Building on previous initiatives mostly undertaken by the 
World Health Organization, we conducted interviews and in-depth research on 35 
NITAGs worldwide and built an assessment framework with 48 indicators to evaluate 
NITAG Alignment with international guidance. Results: The assessment revealed 
that there is a high variability in the degree of NITAG Alignment between countries 
which could not be explained by differences in GDP per capita, health expenditure 
per capita, or geographic location. Countries with a reasonably well-aligned NITAG 
have a higher proportion of the WHO-recommended and additional vaccines in their 
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Objectives: A growing number of health technologies are coming to market 
with limited, yet promising, clinical data. Coverage with evidence development 
(CED), a conditional interim reimbursement scheme linked to research to reduce 
uncertainty, has been increasingly explored by payers worldwide. The objective 
was to summarize CED programs worldwide, and report final reimbursement deci-
sions. MethOds: A search was conducted using published literature, websites and 
grey literature to identify CED programs worldwide from 1998 to 2012. Results: 
Seventy-four CED schemes were identified in Canada (n= 23), Sweden (n= 16), United 
States (n= 14), UK (n= 11), Australia (n= 4) and Europe (n= 6). CED schemes were found 
in oncology (n= 21), heart disease (n= 12), diabetes (n= 10), Neurological disorders 
(n= 7), multiple sclerosis (n= 2), mental health (N= 3), rheumatoid arthritis (N= 1), 
and other (N= 18). Drugs, imaging techniques, surgical procedures, and devices 
were most commonly evaluated. Most CED programs aimed to address more than 
one type of uncertainty. The most commonly encountered uncertainty was clini-
cal benefit, followed by value for money, adoption and diffusion, and affordability. 
Study designs included interventional, clinical, observational, and economic studies. 
CED programs were generally managed by independent, government-funded non-
profit research organizations, university-based academic centers, or professional 
societies. In only 39% (N= 28) of the identified CED schemes, study outcomes and 
funding decisions were reported. In 74% (N= 17) of reported cases, the technology 
evaluated was successfully funded. One technology (lung volume reduction surgery) 
was only funded in a subgroup, and one technology was funded with price reduc-
tion. On many accounts CED has proven challenging to implement. cOnclusiOns: 
Although a large number of CED activities were identified, detailed information, 
especially the study outcomes and final reimbursement decision, only limited infor-
mation of final decisions was publically available. CED is a promising mechanism to 
reduce uncertainty and aid timely patient access, but with emerging implementa-
tion challenges.
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managed entRy agReements in uk, italy and sPain
Tolley C., Palazzolo D.
Quintiles Consulting, Reading, UK
Objectives: To compare Managed Entry Agreements (MEAs) in the UK, Italy, and 
Spain, and analyse the type of MEAs, number of agreements, and therapy areas in 
which they exist. Finally, to determine MEA impact on market access delay in these 
countries. MethOds: HTA databases were searched for types and quantities of 
MEAs (publicly available). The data were analysed by indication, and country spe-
cific knowledge applied, to quantify the average delay to market access. Results: 
All types of MEA have been granted previously in the UK, the majority were non-
outcomes based (76%). In Italy, and Spain, all MEA’s were outcomes based, with 
Italy focused purely on risk-sharing agreements. UK has 42 MEA’s since 2000, Italy 
has 44 MEAs since 2006 and Spain has 9 MEAs since 2010. Of 95 MEAs, 56% were for 
oncology drugs, 12% musculoskeletal, 10% ophthalmology, 7% CNS, 5% respiratory 
and 10% other therapy areas. NICE average time to HTA decision is 21 months, and 
is delayed up to 10 months depending on the type of MEA. AIFA average time to HTA 
decision is 8 months; however MEAs are part of the pricing negotiation, so it may 
be a way to gain market access faster. In Spain, the average time to HTA decision 
is 8 months with decisions for drugs with double pricing arrangements taking on 
average 14 months. For high cost hospital and orphan drugs, the delay can be up to 
a year. cOnclusiOns: Negative reimbursement decisions can have a significant 
impact on achieving market access, and revenue generation. MEAs represent an 
avenue for overcoming these negative decisions and market access for high cost 
medicines. Companies aiming for MEAs in UK, Italy, and Spain, should be aware of 
the potential market access delay and the precedence of MEAs that the payers in 
these countries are amenable to.
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Objectives: The aim of this project was to evaluate risk-sharing agreements that 
are currently being negotiated in Europe between health care authorities and the 
pharmaceutical industry. MethOds: A literature review of the grey literature 
(reports of the Organization for Economic Co-operation and Development and WHO 
Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies) as 
well as peer-reviewed literature (PUBMED) was done to explore the background of 
this topic. Semi-structured interviews were conducted with representatives of the 
pharmaceutical industry, consultant agencies and health care authorities to get 
their opinions about the current state of risk-sharing agreements. Results: The 
study identified multiple problems in risk-sharing agreements such as insufficient 
terminology and methodology, the absence of adequate infrastructure for imple-
mentation and a lack of trust and dialogue between the establishing parties: health 
care authorities and pharmaceutical industry. These issues question the crucial con-
cept of sharing the risks equally and disgrace the agreements, even though it would 
be of great value to overcome current challenges. Such agreements could help the 
health care authorities to keep within their budget while still providing innovative 
pharmaceutical products/treatments to the patients. In addition, the pharmaceuti-
cal industry would have the opportunity to bring its products to the market and 
patients would benefit from adequate pricing and reimbursement. cOnclusiOns: 
In spite of the current problems, the popularity of risk-sharing agreements in Europe 
is growing fast and the future is bright. For this reason there is a strong need for 
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dations is cost-effectiveness information. Currently in Poland there is no specific 
formal threshold for orphan designations, there is only a general cost-effectiveness 
threshold that equals 3 x GDP per capita for ICUR/QALY (for CUA) or ICER/LYG (for 
CEA), which in 2014 is approximately € 26 800. We extracted data on orphan drugs 
from our database of medical technologies assessments from 2009 to March 2014. 
Data on the cost-effectiveness (QALY / LYG) were put together with the decision of 
reimbursement. On the basis of these data the threshold of cost effectiveness in 
Poland for orphan designations was determined and summarized with the cost-
effectiveness thresholds current for a given time interval. Determination of the 
threshold of cost effectiveness for orphan designations, that would be different 
(higher) than the generally accepted cost-effectiveness threshold (due to high price 
of orphan drugs to provide value for money is unlikely), is particularly important 
from an ethical point of view, because of substantial therapeutic meaning of these 
drugs and/or absence of other treatment options of proven benefit for the disease.
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Objectives: The slow reaction of French authorities to the “Mediator saga” 
in France led to investigations that questioned the way conflicts of interest are 
reported. This policy research reviewed the Loi Bertrand, known as French Sunshine 
Act, and reported case law from the French Council of State (COS) related to conflict 
of interest in HTA recommendations. MethOds: Literature review and analysis of 
recent laws and decrees were conducted to understand French policy in the field 
of conflict of interest. A review of COS’ decisions related to conflicts of interest 
among members of HAS commissions was performed. Results: France imple-
mented the Loi Bertrand in May 2013 with the aim of specifying the scope of disclo-
sure obligations. It affects most of the agreements concluded between health care 
professionals and companies and covers a vast range of health products. Six cases 
examined by the COS were analyzed, most of them related to removal of products 
from refundable list. Four cases led to suspension or invalidation of decisions based 
on HAS recommendations due to conflicts of interest. In the two other cases the 
HAS provided the declarations of interest when required by the COS and the COS 
considered the conflicts of interest as irrelevant for the decision. It appears that 
the COS based its decisions on two main criteria: the acknowledgement of negative 
conflict of interest (link with competitors) and the unavailability of declarations 
of conflict of interest, which have to be provided by latest when required by legal 
authorities. cOnclusiOns: The strengthening of the regulation on declarations 
of interest might lead to more transparency but also more cases ruled by the COS.
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caused by vaccines: do We Have tHe RigHt assessment aPPRoacH 
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Objectives: Vaccination not only results in direct protection to those being vac-
cinated, it also has the potential of inducing indirect protection among unvaccinated 
individuals (= herd protection or positive externality). However, negative unintended 
consequences or externalities may also result from vaccination programmes (e.g. 
rebound effects). It is our purpose to present how and when these positive and 
negative externalities can be observed and measured. MethOds: We first identify 
under what conditions herd protection is most likely to occur. We then explore how 
negative rebound effects can also be manifested. Detailed illustrations of both posi-
tive and negative effects are presented for different infections in relation to mass 
vaccination programmes. Lastly, we discuss methods for observing and measuring 
these externalities. Results: Optimal herd protection is likely to be observed when 
the vaccine has a high quality-induced immunity, substantial effect on the force of 
infection, and appropriate vaccine coverage and distribution. Example: HPV vac-
cination of 12-16 year old girls resulted in a 50% decrease of anogenital warts in 
15-19 year aged adolescents in Denmark observed over a 4-year period. Rebound 
effects may potentially occur due to vaccine-related age shifting, decreased natural 
immunity, serotype replacement, low-medium coverage and non-homogeneous 
vaccine distribution. Example: increased herpes zoster incidence in elderly post-
varicella vaccine introduction. Those externalities can be captured through observa-
tional studies using real-life data, or may be estimated using dynamic transmission 
modelling techniques. cOnclusiOns: Limitations are inherent in those studies 
and involve substantial ambiguity in the process of observing and quantifying the 
indirect effects, making accurate evaluation troublesome. However the nature of 
these outcomes could be critical for achieving good economic value when deci-
sion- makers are evaluating a novel vaccine for introduction into a particular region 
or people group. More investigation is needed to identify and develop successful 
assessment methodologies for precisely analysing these outcomes.
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maRket access and ReimbuRsement: tHe incReasing Role of Real-
WoRld evidence
Pietri G., Masoura P.
PAREXEL Consulting, London, UK
Randomised controlled trials (RCTs) have historically been considered the primary 
source of evidence to support market access and reimbursement. However, real-world 
data (RWD) are increasingly being considered by industry and payers. The objectives 
of this research were to review the current perception of RWD across Europe and to 
assess how RWD can support market access and reimbursement. A review of the 
literature, guidelines from European health technology assessment (HTA) agencies 
national immunization programme. Some lower and middle income countries with 
fairly strong alignment scores for recently established NITAGs have basic immunisa-
tion programmes. This study also found that NITAGs are usually developed following 
a stepwise maturing process. cOnclusiOns: Our detailed analysis of data from 35 
countries suggests that, with the right support, all countries – regardless of their GDP/
capita, health expenditures and geographical location – have the potential to establish 
highly performing NITAGs that are well-aligned with international recommendations. 
Well-aligned NITAGs are generally instrumental for having strong immunisation pro-
grammes. Through awareness of its position in this maturation process, a NITAG can 
focus on the appropriate next step for development and strengthening.
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Objective: Advances in early cancer diagnosis and treatment are enabling patients 
to live longer with more fulfilling lives. The value assessment in such cases is 
compelling. Many novel treatments for late-stage cancer also extend life, though 
prognosis may still be poor. The valuation of such life-extending treatments can 
be significantly reduced by health care costs associated with managing patients 
for longer. This study highlights discontinuities between HTA for treatments that 
extend patients’ lives and the NHS’s objective to improve cancer patients’ sur-
vival rates. MethOds And Results: Economic comparison of two treatments 
with an equivalent QALY gain, one that extends life while the other enhances the 
quality of life, indicates that to achieve a common cost per QALY outcome the 
life-extending treatment must be valued lower than the life-enhancing therapy. 
This anomaly arises primarily because the value assessment for life-extending 
treatments includes NHS costs of patient management during their extended life 
in addition to the new treatment costs. For long-term chronic conditions these 
additional costs may be easily offset; however, for severe, debilitating, or terminal 
diseases the impact can be significant. Furthermore, for new treatments added in 
combination to standard care, the greater the cost of existing care the lower the 
value that may be placed on the new life-extending treatment, to the point that 
new therapies may be deemed uneconomical even if available at no cost to the NHS. 
These findings challenge the equitable use of ICERs for HTA including the account-
ing for health services costs during the extended lifetime of a patient achieved with 
a new treatment. cOnclusiOn: Value-based metrics used to appraise new treat-
ments can inadvertently discriminate against life-extending therapies. Use of the 
ICER in HTA can result in inconsistency with health service objectives e.g. the UK 
Government’s goal to improve 1-year and 5-year survival rates for cancer patients.
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cOntext: Theoretical and empirical evidence has demonstrated that health care 
is a major driver of economic growth. The European economic crisis has resulted in 
health care budget cuts conferring consequences for health systems. Preventative 
programmes, and particularly vaccination, are most vulnerable to short-term cuts 
because their benefits are not always immediately identifiable. Although its huge 
public health benefits are recognised, only a minor fraction of the health care budget 
is allocated to vaccination. It has been suggested that cost-effectiveness analy-
ses, as used in HTA as part of recommendations and reimbursement decisions, 
may render a too narrow perspective of the overall economic benefits of vaccina-
tion. Objectives: The aim of this project is to demonstrate that, in addition to 
contributing to health care system sustainability, vaccines have importance for 
wider economic planning. A seven-chapter report was developed to highlight the 
full economic value of vaccination from different perspectives: macro-economic, 
health care system, society… Each chapter is illustrated with existing evidence 
retrieved from peer-reviewed publications. The objective of this report is threefold: 
1) to demonstrate the full economic value of vaccination with real life examples; 2) 
to inform policy-makers on how immunisation contributes to health care systems 
sustainability and efficiency; 3) to launch a call for action for the consideration of 
the full economic value of vaccination. discussiOn: Immunisation programmes 
require adequate value recognition to ensure quick population access and wide 
acceptability. Policy-makers should acknowledge that prevention through vaccina-
tion involves low levels of investment relative to the substantial incremental ben-
efits it procures. As with other preventative interventions, it is difficult to evaluate 
the true economic value of vaccines given a number of benefits are intangible and 
thereby difficult to quantify in pure monetary terms. Taking into account the full 
economic benefits of vaccination will allow understanding why prevention is the 
one of the best ways to find efficiency gains.
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Poland based on ReimbuRsement decisions
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The aim of this study was to identify the cost-effectiveness threshold for an orphan 
designations in Poland. According to criteria specified by the European Medicines 
Agency (EMA) a medicine must meet a strict criteria to qualify for orphan designa-
tion, such as: treatment, prevention or diagnosis of a disease that is life-threatening 
or chronically debilitating; disease prevalence level in the European Union (EU) of 
no more than 5 cases in 10,000 patients is necessary; no satisfactory method of 
disease diagnosis, prevention, treatment or if such method exists, the drug must 
deliver significant benefits to patients. In Poland, orphan drugs undergo full phar-
macoeconomic evaluations and coverage decision processes similar to any other 
innovative medicines. One of the important element of reimbursement recommen-
